Next Article in Journal
QuEChERS Purification Combined with Ultrahigh-Performance Liquid Chromatography Tandem Mass Spectrometry for Simultaneous Quantification of 25 Mycotoxins in Cereals
Next Article in Special Issue
The Anatomical Basis of Paradoxical Masseteric Bulging after Botulinum Neurotoxin Type A Injection
Previous Article in Journal
Limited Link between Oxidative Stress and Ochratoxin A—Induced Renal Injury in an Acute Toxicity Rat Model
Previous Article in Special Issue
Effective Botulinum Toxin Injection Guide for Treatment of Temporal Headache
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessArticle
Toxins 2016, 8(12), 374;

Abobotulinum Toxin A in the Treatment of Chronic Low Back Pain

Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA
Author to whom correspondence should be addressed.
Academic Editor: Cesare Montecucco
Received: 13 October 2016 / Revised: 8 December 2016 / Accepted: 9 December 2016 / Published: 15 December 2016
(This article belongs to the Collection Botulinum Toxins on Human Pain)
Full-Text   |   PDF [232 KB, uploaded 15 December 2016]


Chronic low back pain is a debilitating condition with a complex and multifactorial pathophysiology. Botulinum neurotoxins (BoNTs) have strong analgesic effects, as shown in both animal models of pain and in human beings. A randomized, double-blind, placebo-controlled, parallel format study to investigate the efficacy of abobotulinum toxin A (aboA) in chronic low back pain was conducted. The study cohort consisted of 18 patients who received 100 units of aboA into each of the five lumbar extensor spinae muscles unilaterally or bilaterally (total dose 500 to 1000 units), and 19 who received normal saline of the same volume. The level of pain and quality of life were assessed using the visual analogue scale (VAS) and three questionnaires including the Oswestry Low Back Pain Disability Questionnaire (OLBPDQ). Patients’ perception of improvement was recorded via patient global impression of change (PGIC). The primary outcome measure, the proportion of responders with VAS of <4 at 6 weeks, was not met, but the data was significantly in favor of aboA at 4 weeks (p = 0.008). The total Oswestry score representing quality of life improved in the aboA group compared to the placebo group (p = 0.0448). Moreover, significantly more patients reported their low back pain as “much improved” in the abobotulinum toxin A group (0.0293). View Full-Text
Keywords: low back pain; abobotulinum toxin A; botulinum neurotoxin; randomized controlled trial low back pain; abobotulinum toxin A; botulinum neurotoxin; randomized controlled trial
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Machado, D.; Kumar, A.; Jabbari, B. Abobotulinum Toxin A in the Treatment of Chronic Low Back Pain. Toxins 2016, 8, 374.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top